Management of High-Risk Patients with Diabetes

Assessment of Risk

The American Diabetes Association recommends that an HbA1c of 12.2% indicates severely uncontrolled diabetes with significantly increased risk for both microvascular and macrovascular complications 1, 2
The American College of Cardiology suggests that a 15.1-32.1% risk of cardiovascular events indicates high to very high cardiovascular risk, requiring aggressive intervention 3, 4

The American Diabetes Association recommends setting an initial target HbA1c of 7-8% rather than attempting to normalize glycemia too quickly, which could lead to adverse effects 5, 6
The American Heart Association suggests that the primary focus should be on reducing cardiovascular risk while improving glycemic control 3, 4

The American Diabetes Association recommends starting metformin immediately as the foundation of therapy, unless contraindicated, with a modest reduction in diabetes-related endpoints and all-cause mortality in overweight/obese adults 2, 6
The American College of Cardiology suggests adding a GLP-1 receptor agonist with proven cardiovascular benefit, such as liraglutide, semaglutide, or dulaglutide, which have demonstrated significant reduction in major adverse cardiovascular events (MACE) in cardiovascular outcomes trials 3, 4, 7
The American Heart Association recommends adding an SGLT2 inhibitor with proven cardiovascular benefit, such as empagliflozin, canagliflozin, or dapagliflozin, which have demonstrated reduction in cardiovascular events and heart failure hospitalizations 3, 4, 7

The American Diabetes Association suggests monitoring blood glucose frequently, ideally with self-monitoring of blood glucose (SMBG) multiple times daily, and scheduling follow-up within 2-4 weeks to assess response to therapy and adjust medications as needed 2, 9
The American Heart Association recommends reassessing HbA1c after 3 months of therapy to determine if treatment goals are being achieved, and monitoring for hypoglycemia, especially if insulin is initiated 2, 6, 9

The American College of Cardiology recommends optimizing blood pressure control to target <130/80 mmHg, and initiating high-intensity statin therapy regardless of baseline LDL levels 3, 4
The American Heart Association suggests considering low-dose aspirin for secondary prevention if established ASCVD or primary prevention in high-risk patients, and providing smoking cessation counseling if applicable 3, 6
The American Diabetes Association recommends lifestyle modifications including weight loss, dietary changes, and increased physical activity 2, 6